TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07220785: A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy (LAGO)

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 28 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT07220785 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07220785 Rescue Dossier →